LAP016B_TYKERB_ONCOLOGY
Drug
Novartis Pharma AG
Total Payments
$237,624
Transactions
6
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $89,109 | 3 | 0 |
| 2019 | $148,515 | 3 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $237,624 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CLAP016B2301 | Novartis Pharma AG | $237,624 | 0 |
Top Doctors Receiving Payments for LAP016B_TYKERB_ONCOLOGY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rochester, MN | $237,624 | 6 |
Ad
Manufacturing Companies
- Novartis Pharma AG $237,624
Product Information
- Type Drug
- Total Payments $237,624
- Total Doctors 0
- Transactions 6
About LAP016B_TYKERB_ONCOLOGY
LAP016B_TYKERB_ONCOLOGY is a drug associated with $237,624 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2019 to 2020. In 2020, $89,109 was paid across 3 transactions to 0 doctors.
The most common payment nature for LAP016B_TYKERB_ONCOLOGY is "Unspecified" ($237,624, 100.0% of total).
LAP016B_TYKERB_ONCOLOGY is associated with 1 research study, including "CLAP016B2301" ($237,624).